Related Articles
The prolactin receptor mediates HOXA1-stimulated oncogenicity in mammary carcinoma cells
In vitro studies of a prolactin antagonist, hPRL-G129R in human breast cancer cells.
In vivo studies of the anti-tumor effects of a human prolactin antagonist, hPRL-G129R
DMBA promotes ErbB2‑mediated carcinogenesis via ErbB2 and estrogen receptor pathway activation and genomic instability
Rassf3 is responsible in part for resistance to mammary tumor development in neu transgenic mice